On May 26, 2025 Lupin Limited (Lupin) reported it will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025 (Press release, Lupin, MAY 26, 2025, View Source [SID1234653379]). The presentation titled "A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors," will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session. It can be viewed at Poster Board #422 on June 2, 2025, from 1.30 to 4.30 pm (CDT).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key findings from the study include:
LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, with desirable PK/PD profile and no impact of food on the pharmacokinetics.
The maximum tolerated dose, recommended phase 2 dose was determined based on safety, efficacy, PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors.
"We are delighted to share the initial results from Phase I study of our PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. We are committed to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to- treat cancers," said Vinita Gupta, CEO.
Current data from Lupin indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a SAM-competitive PRMT5 inhibitor. Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs.
Details of the Presentation:
Date and time: June 2, 2025, 1:30 pm – 4:30 pm (CDT)
Location: Hall A – Posters and Exhibits | McCormick Place, Chicago, IL
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track: Small Molecules
Clinical Trial Registration Number: CTRI/2023/07/054753
Doi: 10.1200/JCO.2025.43.16_suppl.3107
Abstract Number: 3107
Poster Board Number: 422
Abstract link: View Source